Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib with Anlotinib in EGFR-TKIs Resistant NSCLC
NCT06182761Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Zhongshan Hospital, Fudan University. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06182761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182761.